Research programme: antibacterials - Astellas Pharma/Sumitomo Pharma
Alternative Names: 2-aryl carbapenems; SM-295291; SM-368589; SM-369926; SM-375769Latest Information Update: 05 Apr 2022
At a glance
- Originator Astellas Pharma; Dainippon Sumitomo Pharma
- Developer Astellas Pharma; Sumitomo Pharma
- Class Carbapenems
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections